New Approach Methodologies (NAMs)

New Approach Methodologies (NAMs) is the umbrella term regulators and researchers use for non-animal or human-biology-based technologies developed to generate the safety and efficacy data that toxicology and pharmacology studies have traditionally obtained from live-animal testing. The category spans four broad technology families: in vitro assays using human or animal cell lines, microphysiological systems (“organ-on-a-chip” devices that model the structure and function of human tissue), in silico/computational models (including AI-driven predictive toxicology), and human-relevant cell-based models such as organoids and induced pluripotent stem cell (iPSC) lines. NAMs is a regulatory-science term, not a scientific-methods term in the abstract sense — a method counts as a NAM in the sense used here because a regulator (principally FDA) is evaluating or accepting it as a candidate replacement for a specific animal-testing requirement, not merely because it happens to avoid using animals.

Operational definition

A technology or method is a NAM, for regulatory-submission purposes, when it meets both of the following:

• It generates data relevant to predicting a chemical, drug, or biologic’s safety, toxicity, or efficacy in humans without using a live animal for that specific data point — via in vitro, in silico, ex vivo, or human-cell-based means.
• It is being developed, qualified, or applied specifically in place of, or alongside, an animal study that a regulatory pathway would otherwise require or expect — the “new approach” framing is relative to the existing animal-testing default in that pathway, not a claim of general scientific novelty.

This second criterion is what distinguishes a NAM from a non-animal method used purely for basic-research hypothesis generation with no regulatory-submission role — the latter may use identical underlying technology (e.g. a cell-based assay) but isn’t functioning as a NAM in the regulatory-science sense until it’s positioned to substitute for or supplement a required animal study.

Regulatory momentum: FDAMA 2.0 and the 2025 roadmap

Two developments moved NAMs from a research-community interest to an active regulatory-policy track:

• FDA Modernization Act 2.0, signed into law December 29, 2022, amended the Federal Food, Drug, and Cosmetic Act’s Investigational New Drug (IND) and Biologics License Application (BLA) provisions to remove the longstanding statutory requirement that safety and efficacy data come specifically from animal studies — sponsors may now submit non-animal test data, including cell-based assays and computational models, where scientifically justified. The Act permits this; it does not itself mandate a shift away from animal testing.
• FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies, released April 2025, set out a 3-5 year agency ambition to make certain animal studies the exception rather than the default expectation, starting with monoclonal antibodies and other biologics where extensive animal toxicology testing has historically been required, with plans to extend the approach to other biologics and eventually small-molecule chemical entities. The roadmap frames FDA collaboration with NIH and other agencies through the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) as central to validating NAM data packages for regulatory acceptance.

Sourcing note: FDA.gov’s own hosted copy of the April 2025 roadmap could not be directly retrieved in this research pass (a recurring access issue, not evidence the document doesn’t exist); the summary above is corroborated across multiple independent secondary sources — including AVMA, Holland & Knight’s regulatory-law analysis, and Nature Biotechnology’s coverage — rather than a single outlet, but should be treated as REPORTED-tier pending direct primary-source confirmation, and re-verified directly against fda.gov before citing specific figures, product-category sequencing, or dates as current beyond mid-2026.

NAMs and the 3Rs: the technological embodiment of Replacement

NAMs are not a separate ethical framework from the 3Rs (Replacement, Reduction, Refinement) that already govern research animal use under IACUC protocol review — they are the current generation of technology through which the Replacement principle gets operationalized. Where Reduction and Refinement address animal studies that are still going forward (using fewer animals, minimizing distress), a successful NAM removes the need for the animal study itself for a given data point. In practice, IACUC protocol review already requires investigators to describe consideration of alternatives to animal use as part of standard 3Rs justification; growing NAM availability and regulatory acceptance is what increasingly makes “the alternative wasn’t scientifically adequate yet” a harder claim to sustain for a growing set of study types, particularly in the biologics-safety-testing space FDA’s 2025 roadmap targets first.

Worked examples

• A microphysiological “liver-on-a-chip” system, engineered from human hepatocyte cultures on a perfused microfluidic platform, used to generate hepatotoxicity data submitted as part of an IND package in place of a subset of traditional rodent toxicology testing — a NAM in the regulatory-submission sense, because it is positioned to substitute for a specific animal-testing element.
• A physiologically based pharmacokinetic (PBPK) computational model used to predict human drug exposure from in vitro and physicochemical data, submitted to support dose selection in a regulatory filing without an accompanying animal pharmacokinetics study for that endpoint.
• Under FDA’s April 2025 roadmap, a sponsor developing a monoclonal antibody using a qualified NAM data package (human-relevant in vitro and in silico assays) to satisfy part of the preclinical safety evaluation FDA has historically expected from non-human-primate toxicology studies for that product class.

Counter-example

A toxicology study that uses a smaller, statistically optimized cohort of animals — via improved experimental design rather than a non-animal substitute — is a Reduction strategy under the 3Rs, not a NAM. The study still uses live animals for the same endpoint; nothing has been replaced with a non-animal technology. NAM refers specifically to the replacement technology itself, not to procedural efficiency gains within an animal study that continues to run.

Related terms

• Research Animal — the regulatory category NAMs are developed to reduce reliance on, and the entry covering the full 3Rs framework (Replacement, Reduction, Refinement).
• IACUC — the institutional committee whose protocol review requires investigators to document consideration of alternatives to animal use, the process point where NAM availability is weighed.
• Animal Welfare Act (AWA) — the statutory framework governing animal research that NAMs are, in FDA’s stated policy direction, intended to progressively reduce reliance on for regulated product categories.

For the broader compliance landscape this sits within, see the Research Integrity & Compliance pillar.